Study guide

3.3 Opioids: Intoxication, Overdose, and Withdrawal

IC&RC Alcohol and Drug Counselor CADC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Orientation, IC&RC ADC Exam, and Credential Path

1.1 ADC Credential, IC&RC, and CADC Naming 1.2 Administering Board Application Workflow 1.3 Minimum Standards and Eligibility Boundaries 1.4 ADC Blueprint and Study Priorities 1.5 Exam Format, Items, and Time Management 1.6 Scores, Results, Retakes, and Remediation 1.7 Exam-Day Admission, In-Person Testing, and Remote Testing

2 Chapter 2: Addiction Science, Substance-Use Patterns, and Risk Factors

2.1 Disease Model and Biopsychosocial Frame 2.2 Reward Pathways, Learning, and Reinforcement 2.3 Tolerance, Withdrawal, Craving, and Cross-Tolerance 2.4 Substance-Use Progression and Severity Patterns 2.5 Risk and Protective Factors Across the Lifespan 2.6 Prevention, Case Conceptualization, and Domain Integration

3 Substance Classes, Intoxication, Overdose, and Withdrawal

3.1 Alcohol Intoxication, Overdose, and Withdrawal 3.2 Sedatives, Hypnotics, Anxiolytics, and Cross-Tolerance 3.3 Opioids: Intoxication, Overdose, and Withdrawal 3.4 Stimulants: Intoxication, Crash, and Crisis Risk 3.5 Cannabis, Hallucinogens, and Inhalants 3.6 Polysubstance Use and Overdose Triage

4 Co-Occurring Mental Health, Medical, and Trauma Concerns

4.1 Co-Occurring Symptoms and Integrated Screening 4.2 Suicide, Self-Harm, and Crisis Triage 4.3 Medical Red Flags and Substance-Related Health Concerns 4.4 Trauma-Informed Care and ACEs 4.5 Special Populations, Developmental, and Cultural Factors 4.6 Scope, Referral, Collaboration, and Documentation

5 Screening, Interviewing, and Assessment Instruments

5.1 Motivational Assessment Interview Stance 5.2 Screening Purpose and Instrument Selection 5.3 Substance-Use History and Pattern Exploration 5.4 Collateral Information and Testing Interpretation 5.5 Risk, Withdrawal, and Immediate Needs Screening 5.6 Engagement, Culture, and Documentation

6 Diagnosis, Biopsychosocial Assessment, and Level of Care

6.1 Diagnostic Concepts and Scope 6.2 Biopsychosocial Assessment Framework 6.3 Immediate and Ongoing Needs 6.4 Level-of-Care Placement Reasoning 6.5 Case Formulation and Assessment Summary 6.6 Documentation, Referral, and Reassessment

7 Counseling Relationship, Communication, and Motivational Interviewing

7.1 Rapport and the Working Alliance 7.2 Core Communication Skills 7.3 OARS and Reflective Listening 7.4 Ambivalence, Resistance, and Discord 7.5 Change Talk and Stages of Change 7.6 Feedback and Counselor Style

8 Treatment Planning, Case Management, and Referral

8.1 Treatment Plan Anatomy 8.2 Individualized Goals and Objectives 8.3 Relapse Prevention and Continuing Care 8.4 Case Management and Resource Linkage 8.5 Referral and Multidisciplinary Collaboration 8.6 Discharge, Termination, and Continuity of Care

9 Group Counseling, Family Work, and Recovery Pathways

9.1 Group Purpose, Screening, and Norms 9.2 Group Stages, Cohesion, and Facilitation Skills 9.3 Psychoeducation, Skills Groups, and Process Groups 9.4 Family and Support-System Collaboration 9.5 Mutual Help, Peer Support, and Recovery Pathways 9.6 Medication, Culture, and Continuing Care

10 Professional Ethics, Boundaries, and Scope of Practice

10.1 Ethical Frameworks and Decision Making 10.2 Boundaries, Dual Relationships, and Power 10.3 Self-Disclosure, Conflicts of Interest, and Gifts 10.4 Scope of Practice, Competence, and Referral 10.5 Supervision, Consultation, and Team Accountability 10.6 Self-Awareness, Impairment, and Burnout

11 Confidentiality, Documentation, Informed Consent, and Client Rights

11.1 Confidentiality Foundations for ADC Practice 11.2 Releases and Minimum Necessary Disclosure 11.3 Documentation and Record Quality 11.4 Informed Consent and Client Rights 11.5 Mandated Reporting and Safety Exceptions 11.6 Grievances, Records, Storage, and Professional Communication

12 Integrated CADC Case Scenarios and Final Review

12.1 Reading Integrated Case Vignettes 12.2 Blueprint-Weighted Final Review 12.3 Integrated Scenario: First Contact Through Assessment 12.4 Integrated Scenario: Treatment, Referral, and Discharge 12.5 Weak-Domain Remediation and 8-12 Week Study Plan 12.6 Exam Day, Results, and Retake Workflow

3.3 Opioids: Intoxication, Overdose, and Withdrawal

Key Takeaways Explain This Topic AI

Opioids are CNS depressants whose overdose — not withdrawal — is the lethal event, via respiratory depression.

The opioid overdose triad is pinpoint (miotic) pupils, decreased respiration, and decreased consciousness.

Naloxone (Narcan) reverses overdose: 4 mg intranasal, repeat every 2-3 minutes; its short half-life means re-narcotization is possible.

Opioid withdrawal is severely distressing but not usually life-threatening; the COWS (11 items, 0-48) measures its severity.

Medications for opioid use disorder — methadone, buprenorphine, naltrexone — are evidence-based recovery pathways, not failures of recovery.

Last updated: June 2026

Opioids and the lethal-overdose pattern

Opioids include heroin, fentanyl and fentanyl analogs, and prescription analgesics (oxycodone, hydrocodone, morphine, methadone). They act on mu-opioid receptors to produce analgesia, euphoria, sedation, and physical dependence. For the CADC exam, the single most important opioid distinction is overdose versus withdrawal , because their priorities differ completely.

Where alcohol and sedatives have lethal withdrawal , opioids have lethal overdose . The classic opioid overdose triad is:

  • Sign Description
  • Pinpoint (miotic) pupils Constricted pupils, often described as "pinpoint"
  • Respiratory depression Slow, shallow, or absent breathing — the cause of death
  • Decreased consciousness Unresponsive, cannot be roused, "nodding off"

Other overdose signs include cyanosis (blue lips/fingertips), gurgling or "death rattle," and limp body. Fentanyl has driven overdose mortality because it is far more potent than heroin (roughly 50-100 times morphine) and frequently contaminates other drug supplies — counterfeit pills, heroin, cocaine, and methamphetamine — so a user may not know they ingested it. Even more potent analogs such as carfentanil can require multiple naloxone doses and are harder to reverse.

The harm-reduction implication the exam may reference is that fentanyl test strips and naloxone distribution are evidence-based overdose-prevention tools the counselor can educate about and refer to within scope.

Intoxication short of overdose shows drowsiness, nodding, slowed speech, constricted pupils, poor attention, and reduced respiratory effort. The CADC role with people who use opioids includes recognizing immediate and ongoing needs, case management, referral, and collaboration — not giving medication instructions or replacing medical evaluation. One more high-yield contrast: opioids constrict pupils, but in a combined or hypoxic overdose pupils may dilate, so a normal pupil exam never rules out opioid overdose when breathing is compromised.

Naloxone and emergency response

Naloxone (Narcan) is an opioid antagonist that displaces opioids from mu receptors and rapidly reverses respiratory depression. The exam expects you to recognize it as the antidote and to know the overdose response, not to act as a prescriber.

Intranasal naloxone is supplied as a 2 mg or 4 mg single-dose spray; the 4 mg spray is the common community/take-home form.

Re-administer every 2-3 minutes (alternating nostrils for the spray) if there is no response, while waiting for EMS.

Naloxone's duration of action is shorter than many opioids' (especially long-acting agents and potent synthetics) , so respiratory depression can return — "re-narcotization." The person must be monitored and transported even if they wake up.

Naloxone can precipitate acute withdrawal in a dependent person (sudden vomiting, agitation), but reversing a stopped breath always takes priority.

Applied scenario: a client is found in the waiting area barely responsive, with slow breathing and pinpoint pupils after reporting fentanyl use. The best answer is to activate emergency response, administer naloxone if available and trained per agency protocol, support breathing, and call EMS. A weak answer is to begin a treatment-plan discussion, take a detailed family history, or let the client "sleep it off."

Trap: confusing withdrawal discomfort with overdose danger. Opioid withdrawal is dramatic but the breathing-threatening event is overdose. If breathing is compromised, emergency response comes first; if the client is alert but withdrawing, assessment, support, referral, and coordination with withdrawal-management services are the path.

Withdrawal, COWS, and medications for opioid use disorder

Opioid withdrawal is intensely uncomfortable but not typically life-threatening in otherwise healthy adults (dehydration from severe vomiting/diarrhea is the main medical risk). Onset depends on the drug: short-acting opioids (heroin) begin withdrawal in ~8-24 hours and peak around 1-3 days; long-acting opioids (methadone) begin in ~24-48 hours and last longer.

The Clinical Opiate Withdrawal Scale (COWS) is the tool to recognize: an 11-item clinician-rated scale (resting pulse, sweating, restlessness, pupil size, bone/joint aches, runny nose/tearing, GI upset, tremor, yawning, anxiety/irritability, gooseflesh skin) scored 0-48 .

  • COWS score Severity
  • 5-12 Mild
  • 13-24 Moderate
  • 25-36 Moderately severe
  • 37-48 Severe

COWS guides medical timing for starting buprenorphine (induction usually waits for moderate withdrawal to avoid precipitated withdrawal). The CADC does not dose; the value is recognizing that a structured tool drives the medical decision.

Medications for opioid use disorder (MOUD) are evidence-based recovery pathways: methadone (full agonist, clinic-dispensed), buprenorphine (partial agonist, often combined with naloxone as Suboxone), and naltrexone (antagonist, including extended-release Vivitrol). The scope-aware exam answer treats MOUD as legitimate recovery — never as "not real recovery" — supports informed choice, and coordinates with qualified prescribers when releases allow.

Language and traps: use person-first language ( person with opioid use disorder, return to use, medication treatment ). Avoid stigmatizing terms. The biggest traps are (1) deciding whether medication is "allowed" — eligibility, prescribing, and dosing are outside CADC scope; and (2) framing abstinence-only as the only valid path. The counselor educates generally, refers, coordinates, and documents.

Slow or absent breathing with pinpoint pupils is an overdose emergency.

Naloxone 4 mg intranasal, repeat q2-3 min; expect possible re-narcotization.

Withdrawal is distressing but rarely lethal; COWS (11 items, 0-48) grades it.

MOUD (methadone, buprenorphine, naltrexone) is evidence-based recovery.

Buprenorphine is started only after withdrawal has begun (guided by COWS) to avoid precipitated withdrawal.